| beST prAcTIce | ArTIcLe


Juvéderm VOLUMA last longer (for at least 12–18 months) than do those of other Juvéderm products, while retaining all of the benefits of the other Juvéderm products, such as smooth and even flow, malleability, resorbability, and reversibility. It is also considered easy-to-use and is highly satisfactory to patients4, 16


(Figures 4 and 5; Tables 2 and 3). Juvéderm VOLUMA is supplied with cannulae and


needles, and thus provides options to suit the preferences and experience of the clinician. pre- and post-treatment recommendations are similar to those of other Juvéderm products and hyaluronic acid fillers in general. Unlike most other hyaluronic acids, Juvéderm VOLUMA is intended for subcutaneous, sub- or intra-fat pad, and above the periosteum use. It combines the smooth, cohesive features of other members of the Juvéderm family with its volumising properties. No migration has been observed either in published clinical trials or in the experience of the consensus group participants4, 16


. This differentiates Juvéderm VOLUMA


from restylane SubQ, which participants noted to be potentially unstable at injections sites. For more superficial treatments, other hyaluronic acids may be more appropriate and can be used either before or after treatment with Juvéderm VOLUMA. experienced clinicians consider Juvéderm VOLUMA suitable for a broad range of patients who require volume restoration or creation. They recommend using the product primarily in the malar area, chin, jaw, and pre-jowl sulcus. Further, it is suggested that new users begin with malar enhancement in patients with a mild to moderate degree of volume loss.


Conclusions As a highly robust, smooth, viscous, and cohesive hyaluronic acid gel formulation, Juvéderm VOLUMA is one of the foundations of the current aesthetic treatment paradigm that considers volume restoration and contouring a paramount goal in facial rejuvenation — whether the volume deficits result from ageing, weight-loss, congenital defects, or HIV-associated lipoatrophy. As Juvéderm VOLUMA is a volumising agent, technical considerations concerning use differ substantially from dermal fillers. Therefore, potential users should undergo specific training in the use of Juvéderm VOLUMA before treating patients. It is also recommended that less experienced users begin treatments with patients who exhibit less severe volume loss, and restrict their treatments to the malar area. Overall, the most suitable facial areas for treatment with Juvéderm VOLUMA are the malar–midface area, chin, jaw, and pre-jowl sulcus. The use of Juvéderm VOLUMA in facial volumising is


also consistent with a multimodal approach to address the spectrum of changes associated with ageing. Within this framework, neurotoxins play an essential role in managing dynamic changes associated with hypertrophic muscle activity, and a range of dermal fillers can be used to reduce the appearance of static lines and folds. As a volumising agent, Juvéderm VOLUMA retains the reversible and resorbable qualities of hyaluronic acids, while offering a high level of effectiveness, characterised by long-lasting outcomes, a lack of migration and stability at the injection site, and an excellent safety profile.


E Acknowledgements The Juvéderm Voluma Study Investigators Group: Pierre André, MD, Paris, France; Benjamin Ascher, MD, Paris, France; Matilde Sánchez Bayton, DRA, Madrid, Spain; Ma Teresa Balda Etxarri, DRA, San Sebastian, Spain; Ekaterina Olegovna Gutop, MD, Jaroslav, Russia; Klaus Hebold, MD, Köln, Germany; Alexey Litvin, MD, Moscow, Russia; Leonardo Marini, MD, Trieste, Italy; Didier Potdevin, MD, CGP, Ohain (Brussels), Belgium; Adrian M. Richards, MD, Princes Risborough, England; Christopher Rowland-Payne, MD, London, England; Leonie W. Schelke, MD, CGP, Amsterdam, Netherlands; Massimo Signorini, MD, Milan, Italy.


E Illustrations in Figures 5 and 6 were developed by Signature Business Solution, LLC.


E Funding for writing and editorial support was provided by Allergan, Inc., Irvine, California. Writing and editorial assistance was provided by Paula G. Davis, PhD and Ramana Yalamanchili, PhD, MBA of Health Learning Systems, Parsippany, NJ.


E Declaration of interest Dr Hervé Raspaldo is a consultant for Allergan, Inc. and has received grants for medical studies, conference presentations, and participation in videos. Dr Klaus Hoffmann is a consultant for Allergan, Inc. and has received grants for medical studies, conference presentations, and participation in videos. Dr Sandrine Sebban is a consultant for Allergan, Inc. and has received grants for medical studies, conference presentations, and participation in videos.


References


1. Carruthers JD, Glogau RG, Blitzer A; the Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies---consensus recommendations. Plast Reconstr Surg 2008; 121(suppl 5): 5S–30S


2. Donath AS, Glasgold RA, Glasgold MJ. Volume loss versus gravity: new concepts in facial aging. Curr Opin Otolaryngol Head Neck Surg 2007; 15(4): 238–43


3. Fagien S, Raspaldo H. Facial rejuvenation with botulinum neurotoxin: an anatomical and experiential perspective. J Cosmet Laser Ther 2007; 9(Suppl 1):23–31


4. Raspaldo H. Volumizing effect of a new hyaluronic acid sub-dermal facial filler: a retrospective analysis based on 102 cases. J Cosmet Laser Ther 2008; 10(3): 134–42


5. Raspaldo H. New Era in Facial Contouring With Injectable Substances: Interest of Volumizing Injections and 3D-Photos. Poster presentation: European Academy of Facial Plastic Surgery, 2–5 September 2009; Porto, Italy


6. Clemente C. The neck and head. In: Anatomy: A Regional Atlas of the Human Body. Philadelphia: Lippincott Williams & Wilkins, Inc.; 1997


7. Gladstone HB, Wu P, Carruthers J. Background information on the use of esthetic fillers. In: Carruthers J, Carruthers A. eds, Soft Tissue Augmentation: Procedures in Cosmetic Dermatology. Philadelphia: Elsevier Saunders; 2005


8. Carruthers A, Carruthers J. Botulinum toxin type A for treating glabellar lines in men: a dose ranging study. Poster presentation: American Academy of Dermatology’s 61st Annual Meeting, 21–26 March 2003; San Francisco, California


9. Raspaldo H, Bettens R, Giordano P. Midface Enhancement. In: Vuyk HD, Lohuis PJ. eds, Facial Plastic & Reconstructive Surgery. New York: Oxford University Press; 2008


10. Monheit GD, Coleman KM. Hyaluronic acid fillers. Dermatol Ther 2006; 19(3): 141–50


11. Tezel A, Fredrickson GH. The science of hyaluronic acid dermal fillers. J Cosmet Laser Ther 2008; 10(1): 35–42


12. Smith KC. Practical use of Juvéderm: early experience. Plast Reconstr Surg 120(6 suppl): 67S–73S


13. Falcone SJ, Berg RA. Crosslinked hyaluronic acid dermal fillers: a comparison of rheological properties. J Biomed Mater Res A 2008; 87(1): 264–71


14. Restylane SubQ: Instructions for Use. Uppsala, Sweden: Q-Med AB


15. Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M,


Smith S. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003; 29(6): 588–95


16. Bechara FG, Gambichler T, Brockmeyer NH, Sand M,


Altmeyer P, Hoffmann K. Hyaluronic acid new formulation: experience in HIV-associated facial lipoatrophy. Dermatology 2008; 217(3): 244–9


17. Juvéderm Voluma: Instructions for Use. Pringy, France: Allergan


18. Ascher B, Coleman S, Alster T et al. Full scope of effect of facial lipoatrophy: a framework of disease understanding. Dermatol Surg 2006; 32(8): 1058–69


19. Gladstone HB, Cohen JL. Adverse effects when


injecting facial fillers. Semin Cutan Med Surg 2007; 26(1): 34–9


20.Juvéderm Ultra 4: Instructions for use. Pringy, France: Allergan


21. Lowe NJ, Maxwell CA, Patnaik R. Adverse reactions to dermal fillers: review. Dermatol Surg 2005; 31(11 Pt 2): 1616–25


22. Cohen JL. Understanding, avoiding, and managing


dermal filler complications. Dermatol Surg 2008; 34(Suppl 1): S92–9


23. Raspaldo H, Aziza R, Belhaouari L et al. How to achieve synergy between volume replacement and filling products for global facial rejuvenation. J Cosmet Laser Ther 2011; 13(2): 77–86


prime-journal.com | November/December 2011 ❚


27


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84